Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Clinical Oncology

• Publication date

  1998-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1998.16.11.3570PMID 9817277
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• O6-Alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications

  2005cited by this paper
• Treatment of subcutaneous and intracranial brain tumor xenografts withO6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea

  2004cited by this paper
• Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine

  2004cited by this paper
• O6-benzylguanine and its role in chemotherapy.

  1997cited by this paper
• Regulation of O6-methylguanine-DNA methyltransferase by methionine in human tumour cells.

  1997cited by this paper
• Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine.

  1996cited by this paper
• Activity of temozolomide in the treatment of central nervous system tumor xenografts.

  1995cited by this paper
• Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase.

  1995cited by this paper
• Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine.

  1993cited by this paper
• Regulation of repair of alkylation damage in mammalian genomes.

  1993cited by this paper
• Enhancement of Nitrosourea Activity in Medulloblastoma and Glioblastoma Multiforme

  1992cited by this paper
• Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation.

  1992cited by this paper
• Repair of DNA containing O6‐alkylguanine

  1992cited by this paper
• Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.

  1992cited by this paper
• Comparison of the inactivation of mammalian and bacterial O6-alkylguanine-DNA alkyltransferases by O6-benzylguanine and O6-methylguanine.

  1991cited by this paper
• Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents.

  1991cited by this paper
• Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents.

  1990cited by this paper
• DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal.

  1990cited by this paper
• Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents.

  1990cited by this paper
• Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea.

  1990cited by this paper
• O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts.

  1989cited by this paper
• Potentiation of nitrosourea cytotoxicity in human leukemic cells by inactivation of O6-alkylguanine-DNA alkyltransferase.

  1988cited by this paper
• Cellular resistance to chloroethylnitrosoureas, nitrogen mustard, and cis-diamminedichloroplatinum(II) in human glial-derived cell lines.

  1987cited by this paper
• Inhibition of O6-alkylguanine-DNA-alkyltransferase activity potentiates cytotoxicity and induction of SCEs in human glioma cells resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea.

  1987cited by this paper
• Inactivation of O6-methylguanine-DNA methyltransferase and sensitization of human tumor cells to killing by chloroethylnitrosourea by O6-methylguanine as a free base.

  1986cited by this paper
• Therapy of adult malignant brain tumors: what have the clinical trials taught us?

  1986cited by this paper
• Effect of O6-alkylguanine pretreatment on the sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents.

  1986cited by this paper
• Reduction of O6-alkylguanine-DNA alkyltransferase activity in HeLa cells treated with O6-alkylguanines.

  1985cited by this paper
• The role of O6-methylguanine-DNA methyltransferase in cell survival, mutagenesis and carcinogenesis.

  1985cited by this paper
• Exposure of HeLa cells to 0(6)-alkylguanines increases sensitivity to the cytotoxic effects of alkylating agents.

  1985cited by this paper
• Chemotherapy of primary brain tumors.

  1985cited by this paper
• Pretreatment of human colon tumor cells with DNA methylating agents inhibits their ability to repair chloroethyl monoadducts.

  1984cited by this paper
• O6-alkylguanine-DNA alkyltransferase activity in human brain and brain tumors.

  1984cited by this paper
• Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.

  1983cited by this paper
• Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas . A joint radiation therapy oncology group and eastern cooperative oncology group study

  1983cited by this paper
• A simple, rapid, and sensitive DNA assay procedure.

  1980cited by this paper
• DNA crosslinking and cytotoxicity in normal and transformed human cells treated with antitumor nitrosoureas.

  1980cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Experimental evaluation of potential anticancer agents VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia.

  1963cited by this paper

• Research trends in glioma chemoradiotherapy resistance: a bibliometric analysis (2003–2023)

  2025cites this paper
• A flexible dose-response modeling framework based on continuous toxicity outcomes in phase I cancer clinical trials

  2023influential citation
• Advances in DNA damage response inhibitors in colorectal cancer therapy

  2023cites this paper
• A multi-functional hypoxia/esterase dual stimulus responsive and hyaluronic acid-based nanomicelle for targeting delivery of chloroethylnitrosouea

  2023cites this paper
• Editorial: DNA repair and nucleic acid therapeutics in cancer

  2023cites this paper
• CRM and partial order CRM with adaptive rescaling for dose‐finding in immunotherapy trials with a continuous outcome

  2023cites this paper
• Temozolomide Resistance: A Multifarious Review on Mechanisms Beyond O‑6‑Methylguanine‑DNA Methyltransferase.

  2022cites this paper
• From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas

  2021cites this paper
• A narrative review of research progress on drug therapies for glioblastoma multiforme

  2021cites this paper
• A Curve-Free Bayesian Decision-Theoretic Design for Phase Ia/Ib Trials Considering Both Safety and Efficacy Outcomes

  2020cites this paper
• A Curve-Free Bayesian Decision-Theoretic Design for Phase Ia/Ib Trials Considering Both Safety and Efficacy Outcomes

  2020cites this paper
• Disentangling the therapeutic tactics in GBM: From bench to bedside and beyond

  2020cites this paper
• Phase 0 and Window of Opportunity Clinical Trial Design in Neuro-Oncology: A RANO Review.

  2020cites this paper
• Envelope Simulation: A New Adaptive Method for Dose Optimization

  2020cites this paper
• DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas.

  2019cites this paper
• Targeting DNA repair in gliomas.

  2019cites this paper
• Precision oncology : oncogenic stat3 signalling in brain tumours

  2019cites this paper
• PAM-OBG: A monoamine oxidase B specific prodrug that inhibits MGMT and generates DNA interstrand crosslinks, potentiating temozolomide and chemoradiation therapy in intracranial glioblastoma

  2018cites this paper
• Noncoding RNAs in DNA Damage Response: Opportunities for Cancer Therapeutics.

  2018cites this paper
• Synthesis and Antitumor Activity Evaluation of a Novel Combi-nitrosourea Prodrug: BGCNU.

  2017cites this paper
• A benchmark for dose finding studies with continuous outcomes.

  2017cites this paper
• Pharmacokinetics and Pharmacodynamics effects of Everolimus and Sorafenib combination : impact of doses and sequence of administration on the combination

  2017cites this paper
• Evaluation of O6-Benzylguanine−Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial

  2017cites this paper
• Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer

  2017cites this paper
• A robust two‐stage design identifying the optimal biological dose for phase I/II clinical trials

  2017cites this paper
• Development of PAC-1 as a privileged agent for combination chemotherapy

  2016cites this paper
• miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectly

  2016cites this paper
• Targeting the DNA Damage Response in Cancer.

  2015cites this paper
• A Phase III study of radiation therapy (RT) and O6-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001

  2015cites this paper
• Targeting DNA Repair Mechanisms to Treat Glioblastoma

  2015cites this paper
• Interstitial chemotherapy for malignant glioma: Future prospects in the era of multimodal therapy

  2015cites this paper
• Overexpression of Nrf2 attenuates Carmustine-induced cytotoxicity in U87MG human glioma cells

  2015cites this paper
• The DNA damage response: implications for tumor responses to radiation and chemotherapy.

  2015cites this paper
• Capturing Cell-Cell Interactions via SNAP-tag and CLIP-tag Technology.

  2015cites this paper
• Dose finding with continuous outcome in phase I oncology trials

  2015cites this paper
• Antineoplastic Effect of Decoy Oligonucleotide Derived from MGMT Enhancer

  2014cites this paper
• Dose-Finding Designs for Phase I Clinical Trials in Oncology and Use of Selective Phenotypying to Increase Power of Genetic Association Studies

  2014influential citation
• MGMT testing—the challenges for biomarker-based glioma treatment

  2014cites this paper
• Inhibition of DNA Repair as a Therapeutic Target

  2014cites this paper
• Chemotherapy for Malignant Gliomas

  2014cites this paper
• Statistical Considerations in the Development and Evaluation of Therapeutic Biomarkers in Cancer

  2013cites this paper
• Update in the treatment of high-grade Gliomas.

  2013cites this paper
• Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer

  2013cites this paper
• O6-Methylguanine-DNA Methyltransferase (MGMT) in Cancer Protection and Therapy

  2013cites this paper
• Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment

  2012cites this paper
• Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.

  2012cites this paper
• Advances in the management of glioblastoma: the role of temozolomide and MGMT testing

  2012cites this paper
• A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study

  2012cites this paper
• DNA repair dysregulation from cancer driver to therapeutic target

  2012cites this paper
• Molecularly targeted therapy in neuro-oncology.

  2012cites this paper
• Chapter 20 – Dose–Effect and Concentration–Effect Analysis

  2012cites this paper
• Brain Tumor Outcome Studies

  2011cites this paper
• Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours

  2011cites this paper
• Factores pronósticos en astrocitomas anaplásicos

  2011cites this paper
• Role of O-6-methylguanine-DNA methyltransferase and effect of O-6-benzylguanine on the anti-tumor activity of cis-diaminedichloroplatinum(II) in oral cancer cell lines

  2010cites this paper
• In vitro comparison of O4-benzylfolate modulated, BCNU-induced toxicity in human bone marrow using CFU-GM and tumor cell lines

  2010cites this paper
• Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents

  2010cites this paper
• Targeting O6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy

  2010cites this paper
• MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma

  2010cites this paper
• Molecularly Targeted Therapies for Astrocytomas

  2010cites this paper
• A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer

  2009cites this paper
• Phase II Trial of Gliadel plus O6-Benzylguanine in Adults with Recurrent Glioblastoma Multiforme

  2009cites this paper
• High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations.

  2009cites this paper
• Current concepts and newer developments in the treatment of malignant gliomas.

  2009cites this paper
• Dose Escalation Methods in Phase I Cancer Clinical Trials

  2009cites this paper
• The expression of MGMT and ErbB2 in human glioma

  2009cites this paper
• Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach

  2009influential citation
• Phase II Trial of Gliadel plus O 6-Benzylguanine in Adults with Recurrent GlioblastomaMultiforme

  2009cites this paper
• DNA repair proteins as molecular targets for cancer therapeutics.

  2008cites this paper
• A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer

  2008cites this paper
• CHAPTER 12 – Inhibition of DNA repair as a therapeutic target

  2008cites this paper
• Phase 1 trial of O6‐benzylguanine and BCNU in children with CNS tumors: A Children's Oncology Group study

  2008cites this paper
• DNA-protein cross-linking by bis-electrophiles

  2008cites this paper
• N6-substituted 2-amino-4-chloro-5-formylpyrimidines: puckered versus planar pyrimidine rings, and hydrogen-bonded aggregation in zero, one, two and three dimensions.

  2008cites this paper
• An Investigation of Proportion Designs Based on a Molecularly Targeted Endpoint

  2008cites this paper
• Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma

  2008cites this paper
• A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.

  2007cites this paper
• Dose–Effect and Concentration–Effect Analysis

  2007cites this paper
• Novel therapies for malignant gliomas.

  2007cites this paper
• Diagnosis and treatment of high-grade astrocytoma.

  2007cites this paper
• O6-methylguanine-DNA-methyltransferase (MGMT) gene therapy targeting haematopoietic stem cells: studies addressing safety issues.

  2007cites this paper
• Novel Microtubule-Stabilizing Agents : Preclinical and Clinical Studies

  2007cites this paper
• Targeting DNA repair as a promising approach in cancer therapy.

  2007cites this paper
• Therapeutic potential of drugs to modulate DNA repair in cancer

  2007cites this paper
• Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.

  2007cites this paper
• Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report

  2007cites this paper
• O4-benzylfolic acid inactivates O6-alkylguanine-DNA alkyltransferase in brain tumor cell lines

  2007cites this paper
• Chemotherapy and delivery in the treatment of primary brain tumors.

  2007cites this paper
• Early Clinical Trial Design Issues: Patient Populations, End Points, and Barriers

  2007cites this paper
• Interstitial chemotherapy with biodegradable BCNU (Gliadel®) wafers in the treatment of malignant gliomas

  2007cites this paper
• Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase.

  2007cites this paper
• MGMT Immunohistochemical Expression and Promoter Methylation in Human Glioblastoma

  2007cites this paper
• Optimal Biological Dose for Molecularly Targeted Therapies

  2007cites this paper
• Optimal Biological Dose for Molecularly-Targeted Therapies†

  2007cites this paper
• Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines.

  2007cites this paper
• The therapeutic potential of O6-alkylguanine DNA alkyltransferase inhibitors

  2007cites this paper
• Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine

  2006cites this paper
• Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy.

  2006cites this paper
• Clinical Trial Designs for Cytostatic Agents and Agents Directed at Novel Molecular Targets

  2006cites this paper
• New treatment strategies for malignant gliomas

  2006cites this paper